Whole Exome Sequencing (WES) is becoming a procedure to help physicians
identify the cause of a genetic condition that has defied diagnosis by
traditional means. The implication here is that exons in the nuclear genome
are sequenced in the hopes that, by comparison with the genomes of nonaffected
individuals, a diagnosis might be revealed.
(a) What are the strengths and weaknesses of this approach?
(b) If you were ordering WES for a patient, would you also include an analysis
of the patient's mitochondrial genome?